is tirzepatide safe for breastfeeding Are GLP-1 While Breastfeeding? Understanding the Facts – PlexusDx Navigating Tirzepatide Breastfeeding Concerns: A

The procedure is FDA-approved, backed by hundreds of clinical and scientific studies, and studied in over 5,500 clinical trial patients

The STEP and SELECT trials, involving thousands of participants, showed that continuing GLP-1 medications prevented weight regain while discontinuation resulted in two-thirds of lost weight returning

Each vial is single-dose discard any remaining solution

Retatrutide has a half-life of approximately 6 days, which supports once-weekly dosing and reaches steady state within 4-5 weeks at each dose level

Its a targeted, scalable solution for weight and metabolic health, built to plug into what your company already provides